Source-grounded facts extracted from Tonix Pharmaceuticals Holding Corp.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Tonix Pharmaceuticals Holding Corp. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
“October 25, 2022, the Company received a letter (the “Notice”) from the Listing Qualifications staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock for the last 30 consecutive business days, the Company no longer meets the requirement to maintain a minimum bid price of $1 per share, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). In accordance with Nasdaq listing rules, the Company has been provided a period of 180 calendar days, or until April 24, 2023, in which to regain complianc”
Daniel Goodman departed as Director at Tonix Pharmaceuticals Holding Corp..
“Dr. Daniel Goodman provided notice to Tonix Pharmaceuticals Holding Corp. (the “Company”) of his intention not to stand for reelection at the Company’s 2022 Annual Meeting of Stockholders (the “2022 Annual Meeting”).”
Carolyn E. Taylor was appointed as director at Tonix Pharmaceuticals Holding Corp..
“On July 16, 2021, the Directors (the “Board”) of Tonix Pharmaceuticals Holding Corp. (the “Company”), increased the size of the Board from seven to eight directors and, upon on the recommendation of its Nominating and Corporate Governance Committee, appointed Carolyn E. Taylor as director of the Company, effective immediately.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.